{"id":62311,"date":"2022-02-15T13:03:44","date_gmt":"2022-02-15T12:03:44","guid":{"rendered":"http:\/\/www.veeva.com\/eu\/?post_type=resources&#038;p=62311"},"modified":"2026-01-27T15:54:12","modified_gmt":"2026-01-27T14:54:12","slug":"veeva-vault-cdms-selected-by-idorsia-to-modernize-clinical-data-management","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/veeva-vault-cdms-selected-by-idorsia-to-modernize-clinical-data-management\/","title":{"rendered":"Veeva CDMS Selected by Idorsia to Modernize Clinical Data Management"},"content":{"rendered":"<p align=\"center\"><em>Fast-growing biopharmaceutical company will use Veeva CDMS for all new trials<\/em><\/p>\n<p><strong>BARCELONA, Spain \u2014 15 Feb. 2022 <\/strong>\u2014 <a href=\"\/eu\/\">Veeva Systems<\/a> (NYSE: VEEV) today announced that Idorsia Pharmaceuticals Ltd (SIX: IDIA) has expanded its use of <a href=\"\/eu\/products\/veeva-clinical-platform\/\">Veeva Clinical Platform<\/a> applications to include <a href=\"https:\/\/www.veeva.com\/eu\/products\/clinical-data-management\/\">Veeva CDMS<\/a> for <a href=\"https:\/\/www.veeva.com\/eu\/products\/veeva-edc\/\">electronic data capture (EDC)<\/a> and <a href=\"https:\/\/www.veeva.com\/eu\/products\/veeva-edc\/\">coding<\/a>. Idorsia is focused on the discovery, development, and commercialization of innovative therapies and needed a modern data management system to support the in-house execution of studies. Veeva CDMS delivers an advanced cloud application suite that will enable Idorsia to accelerate study builds and speed trial execution. <\/p>\n<p>\u201cWith the growing complexity of trial design and rise of clinical data sources, a next-generation clinical data management system is critical,\u201d said Vincent Rolland, associate director, data management programming at Idorsia. \u201cWe\u2019re excited to grow our partnership with Veeva to bring greater speed and agility to our clinical trials.\u201d<\/p>\n<p>Based in Switzerland, Idorsia is a fast-growing biopharmaceutical company with a broad portfolio of novel drugs in its pipeline. The company is shifting from outsourced clinical data management to an in-house model and required flexible cloud technology that equips its team to build and maintain studies across a wide range of products. With Veeva CDMS, Idorsia\u2019s clinical teams will have the capabilities to build studies independently, make mid-study amendments without data migration, and accelerate data cleaning and review.<\/p>\n<p>\u201cIdorsia is a visionary company adopting digital systems to advance data management,\u201d said Richard Young, vice president, strategy, Veeva CDMS. \u201cAs a trusted partner, we\u2019re proud to support their clinical systems strategy with modern applications that can keep up with the pace and complexity of today\u2019s studies.\u201d <\/p>\n<p>Veeva CDMS is part of Veeva Clinical Suite, the industry\u2019s first cloud platform that unifies clinical data management and clinical operations. In addition to selecting Veeva CDMS, Idorsia uses <a href=\"https:\/\/www.veeva.com\/eu\/products\/veeva-ctms\/\">Veeva CTMS<\/a> and <a href=\"https:\/\/www.veeva.com\/eu\/products\/veeva-etmf\/\">Veeva eTMF<\/a> to manage trial content and data on a single cloud platform. Together, these Veeva Clinical Suite applications will streamline execution and enable seamless information sharing across trials.<\/p>\n<p class=\"mb-10\"><strong>Additional Information<\/strong><br \/>\nFor more on Veeva CDMS, visit: <a href=\"\/eu\/products\/clinical-data-management\/\">veeva.com\/eu\/VaultCDMS<\/a><br \/>\nConnect with Veeva on LinkedIn: <a href=\"https:\/\/www.linkedin.com\/company\/veeva-systems\" target=\"_blank\" rel=\"noopener noreferrer\">linkedin.com\/company\/veeva-systems<\/a><br \/>\nFollow @veeva_eu on Twitter: <a href=\"https:\/\/www.twitter.com\/veeva_eu\" target=\"_blank\" rel=\"noopener noreferrer\">twitter.com\/veeva_eu<\/a><\/br>\n<\/p>\n<p class=\"mb-0\"><strong>About Idorsia<\/strong><\/p>\n<p class=\"mt-0\">Idorsia Ltd is reaching out for more \u2013 We have more ideas, we see more opportunities, and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.<\/p>\n<p>Headquartered near Basel, Switzerland \u2013 a European biotech-hub \u2013 Idorsia is specialized in the discovery, development, and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet \u2013 the ideal constellation to translate R&#038;D efforts into business success.<\/p>\n<p>Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1000 highly qualified specialists dedicated to realizing our ambitious targets.<\/p>\n<p class=\"mb-0\"><strong>About Veeva Systyems<\/strong><\/p>\n<p class=\"mt-0\">Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world\u2019s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit <a href=\"\/eu\/\">veeva.com\/eu<\/a>.<\/p>\n<p>###<\/p>\n<p><strong>Contact:<\/strong><\/p>\n<p>Deivis Mercado<br \/>\nVeeva Systems<br \/>\n925-226-8821<br \/>\n<a href=\"mailto:deivis.mercado@veeva.com\">deivis.mercado@veeva.com<\/a>\n<\/p>\n<p>Jeremy Whittaker<br \/>\nVeeva Systems<br \/>\n+49 6950955486<br \/>\n<a href=\"mailto:jeremy.whittaker@veeva.com\">jeremy.whittaker@veeva.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fast-growing biopharmaceutical company will use Veeva CDMS for all new trials.<\/p>\n","protected":false},"featured_media":62326,"parent":0,"template":"","class_list":["post-62311","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-html-content-yes","resource-area-20-clinical-data-management","resource-area-20-vault-platform-area","resource-product-20-edc","resource-product-20-vault-platform","resource-type-news-press-release","resource-type-press-release"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/62311"}],"collection":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":2,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/62311\/revisions"}],"predecessor-version":[{"id":93402,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/62311\/revisions\/93402"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media\/62326"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=62311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}